Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hardeep Singh

Psychiatry Tampa, FL Medical Doctor

NPI 1386708675 CMS profile 17093

16554 N Dale Mabry Hwy, Tampa, FL 33618

Open in the dashboard

General payments

$374,339

1,055 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hardeep Singh of Tampa, FL is reported in the CMS Open Payments database as having received $374,339 across 1,055 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $110,642 230
2024 General $95,383 239
2023 General $58,826 174
2022 General $44,526 159
2021 General $22,998 81
2020 General $25,160 58
2019 General $16,805 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hardeep Singh
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Hardeep Singh were reported at $110,642. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Hardeep Singh Psychiatry median Middle half National median
2019 $16,805 $184 $59–$605 $163
2020 $25,160 $119 $36–$372 $114
2021 $22,998 $143 $43–$576 $132
2022 $44,526 $153 $50–$590 $149
2023 $58,826 $170 $56–$651 $160
2024 $95,383 $179 $57–$673 $164
2025 $110,642 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $107,500 207 payments
  2. ITI, Inc. $70,065 138 payments
  3. Axsome Therapeutics, Inc. $63,162 112 payments
  4. E.R. Squibb & Sons, L.L.C. $44,618 43 payments
  5. Allergan Inc. $39,812 70 payments
  6. Supernus Pharmaceuticals, Inc. $31,994 75 payments
  7. Janssen Pharmaceuticals, Inc $7,073 46 payments
  8. Sunovion Pharmaceuticals Inc. $1,259 53 payments
  9. Teva Pharmaceuticals USA, Inc. $1,244 47 payments
  10. Otsuka America Pharmaceutical, Inc. $1,140 48 payments
  11. Other $6,473 216 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $228,860 116 payments
  2. Consulting Fee $73,588 22 payments
  3. Honoraria $26,850 8 payments
  4. Food and Beverage $23,515 733 payments
  5. Travel and Lodging $21,511 174 payments
  6. Education $15 1 payment
  7. Gift $0 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $88,524 182 payments
  2. Auvelity $62,969 108 payments
  3. VRAYLAR Neuroscience $58,769 94 payments
  4. CAPLYTA Psychiatry $53,597 97 payments
  5. QELBREE Psychology $16,815 43 payments
  6. CAPLYTA Psychiatry $16,468 41 payments
  7. Qelbree Viloxazine Hydrochloride $14,450 30 payments
  8. COBENFY Neuroscience $9,426 24 payments
  9. SPRAVATO $7,040 44 payments
  10. COBENFY Psychiatry/Psychology $3,206 6 payments
  11. Other $13,169 479 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

3,881

Median for Psychiatry & Neurology: 100

Drug cost

$162,556

Median for Psychiatry & Neurology: $2,986

Branded share of claims

19.8%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 53 $80,259
Trintellix Vortioxetine Hydrobromide Brand 17 $10,629
Adderall Xr Dextroamphetamine/Amphetamine Brand 13 $7,741
Xanax Alprazolam Brand 12 $7,637
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 239 $5,861
Aripiprazole Generic 116 $5,622
Alprazolam Generic 810 $4,769
Methylphenidate Hcl Generic 59 $4,344
Clonazepam Generic 337 $2,995
Duloxetine Hcl Generic 171 $2,411

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$26,363 53 —
CAPLYTA
$23,340 — —
Auvelity
$22,694 — —
Qelbree
$14,450 — —
COBENFY
$3,206 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

1,055 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record